OBIO vs. CVRX, ARAY, QIPT, DRTS, PROF, CLPT, DCTH, TELA, RCEL, and ANGO
Should you be buying Orchestra BioMed stock or one of its competitors? The main competitors of Orchestra BioMed include CVRx (CVRX), Accuray (ARAY), Quipt Home Medical (QIPT), Alpha Tau Medical (DRTS), Profound Medical (PROF), ClearPoint Neuro (CLPT), Delcath Systems (DCTH), TELA Bio (TELA), AVITA Medical (RCEL), and AngioDynamics (ANGO). These companies are all part of the "surgical & medical instruments" industry.
Orchestra BioMed (NASDAQ:OBIO) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, community ranking, analyst recommendations, dividends, institutional ownership and media sentiment.
CVRx has a net margin of -123.58% compared to Orchestra BioMed's net margin of -1,779.71%. Orchestra BioMed's return on equity of -58.32% beat CVRx's return on equity.
In the previous week, Orchestra BioMed had 2 more articles in the media than CVRx. MarketBeat recorded 4 mentions for Orchestra BioMed and 2 mentions for CVRx. CVRx's average media sentiment score of 0.30 beat Orchestra BioMed's score of -0.10 indicating that CVRx is being referred to more favorably in the news media.
53.6% of Orchestra BioMed shares are held by institutional investors. Comparatively, 75.3% of CVRx shares are held by institutional investors. 6.7% of Orchestra BioMed shares are held by insiders. Comparatively, 18.9% of CVRx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Orchestra BioMed currently has a consensus price target of $17.00, indicating a potential upside of 256.39%. CVRx has a consensus price target of $16.60, indicating a potential upside of 106.98%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, equities analysts clearly believe Orchestra BioMed is more favorable than CVRx.
CVRx received 10 more outperform votes than Orchestra BioMed when rated by MarketBeat users. However, 100.00% of users gave Orchestra BioMed an outperform vote while only 57.14% of users gave CVRx an outperform vote.
Orchestra BioMed has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, CVRx has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.
CVRx has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.
Summary
CVRx beats Orchestra BioMed on 10 of the 18 factors compared between the two stocks.
Get Orchestra BioMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orchestra BioMed Competitors List
Related Companies and Tools
